Mounjuro tirzepatide injections are the first of their kind for the treatment of diabetes and work very well for weight loss. It works by impacting glucose-dependent insulinotropic polypeptide (GIP) receptors and GLP-1 receptors. It is the first drug to work on both of these.   GIP and GLP-1 are hormones of the gut called incretins and are released in the intestines when we eat. Incretins encourage the production of insulin from the pancreas. GLP-1 increases insulin production which in turn reduces sugar levels in the blood. GLP-1 helps to promote the feeling of being full and delays the emptying of the stomach. This helps to control appetite.   GIP also works to increase insulin release. GIP helps reduce fat accumulation, increases glycogen production (which helps stabilize sugars in the bloodstream), increases bone formation, and reduces acid secretion in the stomach.